Pharmaceutically active compounds as Axl inhibitors
申请人:Lead Discovery Center GmbH
公开号:EP2423208A1
公开(公告)日:2012-02-29
The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides of general formula (I):
and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.
PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS
申请人:Schultz-Fademrecht Carsten
公开号:US20140018365A1
公开(公告)日:2014-01-16
The present invention relates to 1-nitrogen-heterocyclic-2-carboxamides and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the treatment and/or prevention of Axl receptor tyrosine kinase subfamily induced disorders, including cancer and primary tumor metastases, and pharmaceutical compositions containing at least one of said 1-nitrogen-heterocyclic-2-carboxamide derivatives and/or pharmaceutically acceptable salts thereof.